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1360Objective:Controversy remains over the routine use of mediastinoscopy or positron emission tomography in T1
non–small cell lung cancer without lymph node enlargement on computed tomography because the risk of N2
involvement is comparatively low. We aimed to develop a prediction model for N2 disease in cT1N0 non–small
cell lung cancer to aid in the decision-making process.
Methods: We reviewed the records of 530 patients with computed tomography–defined T1N0 non–small cell
lung cancer who underwent surgical resection with systematic lymph node dissection. Correlations between
N2 involvement and clinicopathologic parameters were assessed using univariate analysis and binary logistic
regression analysis. A prediction model was built on the basis of logistic regression analysis and was internally
validated using bootstrapping.
Results: The incidence of N2 disease was 16.8%. Four independent predictors were identified in multivariate
logistic regression analysis and included in the prediction model: younger age at diagnosis (odds ratio, 0.974;
95% confidence interval, 0.952-0.997), larger tumor size (odds ratio, 2.769; 95% confidence interval,
1.818-4.217), central tumor location (odds ratio, 3.204; 95% confidence interval, 1.512-6.790), and invasive ad-
enocarcinoma histology (odds ratio, 3.537; 95% confidence interval, 1.740-7.191). This model shows good cal-
ibration (Hosmer–Lemeshow test: P ¼ .784), reasonable discrimination (area under the receiver operating
characteristic curve, 0.726; 95% confidence interval, 0.669-0.784), and minimal overfitting demonstrated by
bootstrapping.
Conclusions: We developed a 4-predictor model that can estimate the probability of N2 disease in computed
tomography–defined T1N0 non–small cell lung cancer. This prediction model can help to determine the cost-
effective use of mediastinal staging procedures. (J Thorac Cardiovasc Surg 2012;144:1360-4)The wide application of computed tomography (CT) has
increased the detection of T1 (3 cm)1 lung cancers. Surgi-
cal resection is considered the optimal treatment for T1
non–small cell lung cancer (NSCLC) without mediastinal
lymph node (N2) involvement or distant metastasis. How-
ever, patients with T1 lung cancer with N2 involvement
should take definitive concurrent chemoradiation or induc-
tion chemotherapy.2-4 Accurate mediastinal staging is a key
factor for the successful management of NSCLC.
Mediastinoscopy is deemed the gold standard for medi-
astinal lymph node staging.5,6 However, the risk of
morbidity and mortality (2% and 0.08%, respectively)7
cannot be overlooked because of the invasive nature of me-
diastinoscopy. Controversy remains as to whether routine
mediastinoscopy should be performed in patients with T1
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such patients.8,9 Although positron emission tomography
(PET) showed superiority over CT in the mediastinal
staging of NSCLC10,11 and a promise to reduce the need
for invasive staging tools, its high expense is an obstacle
to the routine application in many countries.12 Moreover,
the benefit of PET for CT-defined clinical stage IA in pa-
tients also remains controversial.13
Some studies sought to determine the cost-effective strat-
egies of applying invasive or expensive diagnostic proce-
dures.14,15 To obtain pretest probability of N2 disease is
essential for the cost-effectiveness measurement of subse-
quent diagnostic tests. Therefore, this study aimed to de-
velop a risk prediction model of N2 disease in CT-defined
T1N0 NSCLC.
PATIENTS AND METHODS
Patients
From June 2007 to August 2011, we retrospectively reviewed our data-
base of all patients who underwent resection with curative intention at the
Department of Thoracic Surgery, Fudan University Shanghai Cancer Hos-
pital, Shanghai, China. We routinely performed contrast-enhanced chest
CT scans at the Fudan University Shanghai Cancer Hospital before surgery,
even for the patients who had received CT scans in other hospitals. Other
routine preoperative examinations included cardiopulmonary tests, brain
magnetic resonance imaging or CT, bone scanning, and abdominal CT or
ultrasonography. Lymph nodes were considered to be positive if the short
axis exceeded 1 cm on chest CT images. Peripheral nodules were definedgery c December 2012
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CT scans. Inclusion criteria included (1) NSCLC 3 cm or less in diameter
measured on CT scans without evidence of positive lymph nodes or distant
metastasis (cT1N0M0) and (2) systematic lymph node dissection. Patients
who had adenocarcinoma in situ or minimally invasive adenocarcinoma
histology according to the new lung adenocarcinoma classification16
were excluded (only invasive adenocarcinomas were included). Patients
who received neoadjuvant chemotherapy or radiotherapy were excluded.
Patients with a history of malignant tumors were excluded.
Clinicopathologic data on age, gender, smoking history, family history
of lung cancer, symptoms at presentation, tumor site, tumor size measured
on CT, type of surgery, histology, and lymph nodal status according to path-
ologic reports were collected.
This study was conducted in accordance with the Helsinki Declaration
and approved by the institutional review board of the Fudan University
Shanghai Cancer Center, Shanghai, China. Informed consent was waived
because this was a retrospective analysis.
Statistical Analyses
In univariate analyses, we used Pearson’s chi-square test or the Fisher
exact test to evaluate the correlation between amediastinal lymph nodeme-
tastasis and a categoric variable, and an independent sample t test to assess
the association between N2 involvement and a continuous variable. Vari-
ables with a P value less than .2 were entered into a binary logistic regres-
sion analysis that formed the basis of a prediction model. We used forward
stepwise selection procedures with the likelihood-ratio test. Factors statis-
tically significant at the .05 level remained in the final model.
Calibration (concordance between predicted and observed probabili-
ties) of the final model was determined with the Hosmer–Lemeshow statis-
tic and the calibration plot using 10 equal contiguous risk ranges showing
observed versus predicted probabilities. The discriminative ability of the
model was assessed with the area under the receiver operating characteris-
tic (ROC) curve, which ranges from 0.5 (no discrimination) to 1.0 (perfect
discrimination).
A problem with a predictive model is that the performance is overesti-
mated when assessed on the sample used to build the model.17 We inter-
nally validated this model by bootstrapping, which is reported to be
more efficient than other alternatives, such as cross-validation or split-
sample analyses.17 We applied Harrell and colleagues’18 method of using
bootstrapping to estimate the bias-corrected area under the ROC curve
and the extent of ‘‘overfitting.’’ One thousand bootstrap samples were
drawn, each with a sample size equal to the original (530 in our study),
by randomly sampling 530 subjects with replacement from the original
sample.
We used SPSS for Windows (v. 16.0; Chicago, Ill), Stata (v. SE/11.1;
StataCorp, College Station, Tex), and R (version 2.10.0; R Foundation
for Statistical Computing, Vienna, Austria) for statistical analysis. All tests
were 2-tailed.RESULTS
Patient characteristics are listed in Table 1. A total of 530
patients (251 female and 279 male) were reviewed. TheThe Journal of Thoracic and Carmedian age at diagnosis was 59 years (interquartile range,
13). Tumor size ranged from 0.4 to 3.0 cm (median, 2.0; in-
terquartile range, 1.0). The most common lobar location
was the left upper lobe (30.4%), followed by the right upper
lobe (28.7%). The majority (91.5%) of patients underwent
lobectomy.
The incidence of mediastinal lymph node metastasis
was 16.8% (89/530). In univariate analysis (Table 1),
N2-positive patients were significantly younger than
N2-negative patients (P ¼ .028). The mean tumor diameter
of patients with mediastinal nodal involvement was signif-
icantly larger than those without mediastinal nodal involve-
ment (P< .001). The incidence of N2 disease in patients
with invasive adenocarcinoma was 19.5% compared with
9.6% in patients with other histology (P ¼ .006). Patients
with positive N2 nodes were more likely to be never-
smokers (69.7% vs 58.0%; P¼ .041) and to have centrally
located tumors (18.0% vs 10.2%; P ¼ .036).
Finally, 4 independent predictors were included in the
prediction model after multivariate logistic regression.
Odds ratios, 95% confidence intervals, and P values of sig-
nificant predictors are listed in Table 2. Larger tumor size
(P<.001), central tumor location (P ¼ .002), invasive ad-
enocarcinoma histology (P<.001), and younger age at di-
agnosis (P ¼ .025) were independent predictors of
mediastinal lymph node metastasis.
A formula was developed to estimate the probability
of having mediastinal lymph node metastasis on the
basis of the results of the binary logistic regression
analysis. A score is calculated using tumor diameter,
tumor location, histology, and age at diagnosis:
score ¼3.449þ (1.018 $ diameter)þ (1.164 $ location)
þ(1.263 $ histology)(0.026 $ age). The units for diame-
ter and age are centimeter and year, respectively. If the
tumor is centrally located, location ¼ 1 (location ¼ 0
if the tumor is peripherally located). If the tumor is ad-
enocarcinoma in histology, histology ¼ 1 (histology ¼ 0
for other histology). The likelihood of N2 nodal
involvement is then calculated: likelihood of positive
N2 nodes ¼ eScore/(1 þ eScore). A nomogram to predict
the probability of N2 involvement was also
developed on the basis of the multivariate analysis
(Figure 1). For example, for a 65-year-old patient who
had a peripherally located tumor that is adenocarci-
noma in histology and 2.0 cm in diameter,
score ¼3.449þ (1.018 $ 2)þ (1.164 $ 0)þ (1.263 $ 1)
(0.026 $ 65) ¼1.84, likelihood of positive N2 nodes ¼
e1.84/(1 þ e1.84) ¼ 0.137. We can also refer to the
nomogram and find that the probability is between 0.1
and 0.2.
Hosmer–Lemeshow test of goodness-of-fit was not sig-
nificant (P¼ .784), suggesting a high concordance between
predicted and observed probabilities. The calibration plot
(Figure 2) showed that predicted probabilities closelydiovascular Surgery c Volume 144, Number 6 1361
TABLE 1. Patient characteristics and univariate analyses of
clinicopathologic factors associated with mediastinal nodal metastasis
Variable
All
(n ¼ 530)
N2 positive
(n ¼ 89)
N2 negative
(n ¼ 441) P
Age (y)
Median 59 57 60
IQR 13 11 13 .028
Female 251 44 207 .667
Symptomatic 289 54 235 .202
Never-smoker 318 62 256 .041
Family history 43 3 40 .072
Tumor size (cm)
Median 2.0 2.5 2.0
IQR 1.0 0.9 1.0 <.001
Tumor location
Central location 61 16 45 .036
Upper lobes 313 46 267 .121
Invasive adenocarcinoma 384 75 309 .006
IQR, Interquartile range.
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ranges. The area under the ROC curve (Figure 3), which
measures the model’s accuracy, was reasonable (odds ratio,
0.726; 95% confidence interval, 0.669-0.784). Internal
validation by bootstrapping showed the bias-corrected
area under the ROC curve was 0.717, and the extent of
‘‘over-optimism’’ was minimal (0.009, 1.2%), indicating
that this prediction model holds for future patients.
DISCUSSION
Accurate mediastinal staging is critical for the appropri-
ate management of NSCLC. Although CT achieved only
a moderate diagnostic efficacy,19 there remains controversy
over the routine use of invasive (eg, mediastinoscopy) or ex-
pensive (eg, PET) diagnostic tools in T1 NSCLC without
lymph node enlargement on CT because of the low inci-
dence of N2 involvement. To select the cost-effective strat-
egies of staging, we have to obtain pretest probability of
nodal metastasis. Our center has surgically treated (with
systematic lymph node dissection) a large number of pa-
tients with CT-defined T1N0 NSCLC in the past 5 years.
The current study took this advantage and generated
a risk prediction model including 4 independent predictors
of N2 disease: younger age at diagnosis, larger tumor size,
central location, and invasive adenocarcinoma histology.
The prediction model displays good calibration, reasonableTABLE 2. Independent predictors of mediastinal lymph node
metastasis in binary logistic regression analysis
Variable OR 95% CI P
Age (y) 0.974 0.952-0.997 .025
Tumor size (cm) 2.769 1.818-4.217 <.001
Central location 3.204 1.512-6.790 .002
Invasive adenocarcinoma 3.537 1.740-7.191 <.001
OR, Odds ratio; CI, confidence interval.
1362 The Journal of Thoracic and Cardiovascular Surdiscriminative performance, and minimal optimism demon-
strated by internal validation using bootstrapping. Our pre-
diction model should help to select candidates for different
staging strategies.
Shafazand and Gould20 developed a clinical prediction
rule to calculate the probability of mediastinal lymph
node metastasis. However, their prediction model was not
suitable to estimate the risk of nodal involvement in CT-
defined T1N0 NSCLC in several ways. First, CT findings
were not included in the model because only half of the pa-
tients in their sample received CT scans. Because suspected
mediastinal metastasis on chest x-ray, which was 1 of the 6
predictors in that model, possibly correlated with enlarged
lymph nodes on CT, we could expect the presence of clini-
cal N2 cases if CTwas applied to those patients. Second, the
enrolled patients were not limited to stage T1 only, and tu-
mor size greater than 3.6 cm was used as a risk predictor in
their model. This cutoff value could not stratify patients
with T1 (3 cm in diameter) into high- and low-risk cate-
gories, which is contradictory to our findings that larger tu-
mor size is an independent risk predictor of N2 involvement
in patients with clinical T1N0.
The 4 predictors of N2 disease in our prediction model
were also identified in other studies. De Leyn and col-
leagues21 reported that T1N0 (defined by CT) adenocarci-
noma was more likely to have a positive mediastinoscopy
than T1N0 squamous cell carcinoma. Defranchi and col-
leagues9 retrospectively reviewed 59 cases of N2 disease
in T1 NSCLC and found central tumor location in 41 cases
(69%). A study on 503 patients with completely resected
invasive T1 NSCLC revealed that tumor size independently
affected nodal metastasis.22 Shafazand and Gould20 showed
that age less than 65 years was an independent predictor of
mediastinal lymph node metastasis. Younger patients with
NSCLC were more likely to present with more aggressive
disease and have a lower degree of suspicion of lung cancer,
which might lead to delayed diagnosis.23 Suzuki and col-
leagues24 also revealed that adenocarcinoma histology
and large tumor dimension were predictive factors for path-
ologic N2 in patients with NSCLC with a negative medias-
tinum on CT scans.
However, our prediction model can calculate the proba-
bility of N2 disease, which has direct implications for the
selection of diagnostic tools for patients with CT-defined
T1N0 NSCLC. For example, for a 69-year-old patient
who has a peripherally located tumor that is squamous
cell carcinoma in histology and 1.3 cm in diameter, we cal-
culate a score of3.916, and therefore the predicted proba-
bility of N2 disease is 2.0%, which is low enough for the
patient to go directly to surgery.
If a patient has a moderate risk of nodal involvement (eg,
12%), doctors might advise the patient to receive mediasti-
noscopy because a cost-effectiveness study conducted by
Meyers and colleagues15 suggested that if the risk of N2gery c December 2012
FIGURE 1. Nomogram for predicting the probability of N2 disease in T1 NSCLC. The units for diameter and age are center and year, respectively. If
the tumor is centrally located, location ¼ 1 (location ¼ 0 if the tumor is peripherally located). If the tumor is adenocarcinoma in histology,
histology ¼ 1 (histology ¼ 0 for other histology). Locate patient’s age on ‘‘age’’ axis, and draw a perpendicular line to the ‘‘points’’ axis to determine as-
sociated points. Repeat for all the remaining predictors. Locate sum on the ‘‘total points’’ axis, and draw a perpendicular line to get the predicted probability.
NSCLC, Non–small cell lung cancer.
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good yields (<100,000 dollars per life-year gained). How-
ever, the doctors may deem this risk not high enough to jus-
tify an invasive diagnostic procedure and would rather
prescribe a PET scan first. A meta-analysis estimated that
the pooled sensitivity and specificity of fluorodeoxyglucose
PET for detecting mediastinal lymph node involvement
were 83% and 92%, respectively.10 According to Bayes’
theorem, the post-test probability after a positive PET
scan will be 58.6%; the post-test probability after a negative
PET scan will be 2.5%. A decision can be made at this pointFIGURE 2. Calibration plot. The dashed line indicates prefect concor-
dance between observed and predicted probabilities.
The Journal of Thoracic and Car(mediastinoscopy after a positive PET scan and surgery af-
ter a negative PET scan). However, if the estimated pretest
likelihood of N2 disease for a patient is as high as 50%, the
post-test likelihood even after a negative PET scan will beFIGURE 3. ROC curve for the 4-predictor model. The area under the
ROC curve was 0.726 (95% confidence interval, 0.669-0.784). ROC,
Receiver operating characteristic.
diovascular Surgery c Volume 144, Number 6 1363
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scopy. Therefore, PET scans should not be performed in
patients with high pretest likelihoods of N2 nodal
involvement.Study Limitations
Our study has several limitations. It should be noted that
action thresholds may vary among doctors. For example,
some doctors deem that a patient with a probability less
than 10% of N2 involvement can go directly to surgery,
whereas others might argue a risk of 8% is still too high
to exclude mediastinoscopy. This discrepancy could not
be resolved through our prediction model. However, this
model provides quantified predicted probability, which
can be incorporated in the decision-making process and
help the cost-effective selection of diagnostic strategies.
Another factor worthy of note is that PET scan is now
routinely used in some developed countries, such as the
United States, which may thus limit the generalizability
of this model. However, as we described earlier, this predic-
tion model could provide a pretest probability that can be
used to calculate a posttest probability after a PET scan ac-
cording to Bayes’ theorem. In other words, it can facilitate
the interpretation of PET results and subsequently guide the
selection of invasive diagnostic procedures.
Some may criticize that the c statistic (0.726) of our
model is only fair. Although the discriminative ability of
our model may not be good enough if it is used as
a stand-alone diagnostic test, this simple clinical prediction
model can estimate pretest probabilities of N2 disease,
which would help the selection of subsequent diagnostic
tools. However, our predictionmodel is built retrospectively
and only on Chinese patients with NSCLC. Despite the min-
imal optimism revealed by bootstrapping, further external
validation is still warranted to investigate the generalizabil-
ity of this prediction model.CONCLUSIONS
We developed a 4-predictor model for N2 disease in pa-
tients with T1 NSCLC without lymph node enlargement on
CT scans. The predicted likelihood of N2 nodal involve-
ment has implications for the cost-effective use of diagnos-
tic procedures, such as mediastinoscopy and PET, in staging
mediastinal lymph nodes in CT-defined T1N0 NSCLC.References
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